STOCK TITAN

vTv Therapeutics (VTVT) DEF 14A Filings

VTVT NASDAQ

Here are the DEF 14A proxy statements from vTv Therapeutics Inc. (VTVT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow VTVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTVT filings page.

Rhea-AI Summary

vTv Therapeutics Inc. is asking stockholders to vote at a virtual-only 2026 annual meeting on June 10, 2026. Investors will elect seven directors and vote on ratifying Ernst & Young LLP as independent auditor for the year ending December 31, 2026.

The board is fixed at seven members and includes nominees designated under an Amended Investor Rights Agreement and a 2024 Securities Purchase Agreement, giving key investors specified board nomination rights and requiring supermajority board approval for major corporate actions for three years. The company describes its governance structure, committee composition and independence, director pay (cash retainers plus stock options), and detailed executive compensation for 2025, including employment terms and severance protections for the CEO and CFO. The proxy also outlines ownership of about 3.94 million shares on an as-converted basis, with large positions held by MacAndrews & Forbes and several institutional investors.